| Literature DB >> 31244114 |
Jianzhang Yang1, Marthandam Asokan Shibu2, Lulu Kong3, Jinfeng Luo4, Farheen BadrealamKhan2, Yanhui Huang4, Zheng-Chao Tu4, Cai-Hong Yun3, Chih-Yang Huang2,5,6, Ke Ding1, Xiaoyun Lu1.
Abstract
ZAK is a new promising target for discovery of drugs with activity against antihypertrophic cardiomyopathy (HCM). A series of 1,2,3-triazole benzenesulfonamides were designed and synthesized as selective ZAK inhibitors. One of these compounds, 6p binds tightly to ZAK protein (Kd = 8.0 nM) and potently suppresses the kinase function of ZAK with single-digit nM (IC50 = 4.0 nM) and exhibits excellent selectivity in a KINOMEscan screening platform against a panel of 403 wild-type kinases. This compound dose dependently blocks p38/GATA-4 and JNK/c-Jun signaling and demonstrates promising in vivo anti-HCM efficacy upon oral administration in a spontaneous hypertensive rat (SHR) model. Compound 6p may serve as a lead compound for new anti-HCM drug discovery.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31244114 DOI: 10.1021/acs.jmedchem.9b00664
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446